What is Synchronicity Pharma?
Synchronicity Pharma operates at the intersection of circadian biology and genetic medicine. The company is pioneering a unique class of non-viral, targeted nucleic acid therapeutics designed to modulate biological pathways with high precision. Central to its operations is the proprietary GMAB platform, which enables the delivery of genetic payloads to specific cellular targets. This technological foundation allows the company to address high-acuity medical needs, specifically focusing on sleep-wake disorders associated with neurodivergence and the development of novel interventions for challenging oncological conditions. By targeting the molecular mechanisms of circadian rhythms, Synchronicity Pharma aims to redefine the standard of care for patients suffering from chronic, rhythm-linked pathologies.
How much funding has Synchronicity Pharma raised?
Synchronicity Pharma has raised a total of $38.8M across 2 funding rounds:
Debt
$9.1M
Private Equity
$29.7M
Debt (2014): $9.1M with participation from Bay City Capital, LLC
Private Equity (2016): $29.7M, investors not publicly disclosed
Key Investors in Synchronicity Pharma
Bay City Capital, LLC
A venture capital firm specializing in early-stage and growth-stage investments within the life sciences and biotechnology sectors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Synchronicity Pharma?
With the recent influx of capital, Synchronicity Pharma is poised to scale its clinical development programs and enhance its manufacturing capabilities for its GMAB-based therapeutics. The strategic roadmap emphasizes the advancement of lead candidates into human trials, with a particular focus on validating the efficacy of its circadian-targeted interventions. As the company moves into this next phase of growth, it will likely prioritize partnerships with larger pharmaceutical entities to facilitate late-stage clinical trials and global commercialization. The focus remains on maintaining its competitive edge in the genetic medicine landscape by continuously refining its non-viral delivery mechanisms and expanding its intellectual property portfolio in the circadian rhythm space.
See full Synchronicity Pharma company page
